Lazabemide is an inhibitor of monoamine oxidase B (MAO-B; Ki = 0.084 ?M).1 It is selective for MAO-B over MAO-A (IC50s = 0.02 and 640 ?M, respectively).2 Lazabemide inhibits rat liver MAO-B ex vivo with an ED50 value of 53 nmol/kg.3 It inhibits ischemia-reperfusion injury-induced hydroxyl radical formation in mouse cerebral ventricles when administered at a dose of 3 mg/kg.4
1.Cesura, A.M., Gottowik, J., Lahm, H.W., et al.Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesisEur. J. Biochem.236(3)996-1002(1996) 2.Ozaita, A., Olmos, G., Boronat, M.A., et al.Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liverBr. J. Pharmacol.121(5)901-912(1997) 3.Henriot, S., Kuhn, C., Kettler, C., et al.Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findingsJ. Neural Transm. Suppl.41321-325(1994) 4.Suzuki, T., Akaike, N., Ueno, K., et al.MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in micePharmacology50(6)357-362(1995)